

YUTREPIA - (EQ 0.0265MG BASE/INH ; Powder)

| | | | |
|------------------------------|--|-----------------------------|-----------------------|
| Generic Name | TREPROSTINIL SODIUM | Innovator | Liquidia Technologies |
| Dosage | EQ 0.0265MG BASE/INH ; Powder | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | YUTREPIA is a prostacyclin mimetic indicated for the treatment of: • Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). • Pulmonary hypertension associated with interstitial lung disease (PHILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

YUTREPIA - (EQ 0.053MG BASE/INH,EQ 0.0795MG BASE/INH,EQ 0.106MG BASE/INH ; Powder)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | TREPROSTINIL SODIUM | Innovator | None |
| Dosage | EQ 0.053MG BASE/INH,EQ 0.0795MG BASE/INH,EQ 0.106MG BASE/INH ; Powder | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | YUTREPIA is a prostacyclin mimetic indicated for the treatment of: • Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). • Pulmonary hypertension associated with interstitial lung disease (PHILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events



Please Contact contact@researchdelta.com to get Detailed Information.